Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 25,000 shares of the business's stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $7.15, for a total transaction of $178,750.00. Following the sale, the insider now owns 5,487,993 shares of the company's stock, valued at approximately $39,239,149.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Morningside Venture Investment also recently made the following trade(s):
Get Kezar Life Sciences alerts:- On Monday, February 6th, Morningside Venture Investment sold 40,000 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.88, for a total transaction of $275,200.00.
- On Monday, January 30th, Morningside Venture Investment sold 30,000 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.91, for a total value of $207,300.00.
- On Wednesday, January 25th, Morningside Venture Investment sold 50,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.85, for a total value of $342,500.00.
- On Monday, January 23rd, Morningside Venture Investment sold 80,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.81, for a total value of $544,800.00.
- On Tuesday, January 17th, Morningside Venture Investment sold 6,114 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.79, for a total value of $41,514.06.
- On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total transaction of $33,850.00.
- On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.97, for a total transaction of $84,769.14.
Kezar Life Sciences Price Performance
Shares of KZR stock traded down $0.12 during mid-day trading on Tuesday, hitting $6.71. 178,825 shares of the stock traded hands, compared to its average volume of 620,393. Kezar Life Sciences, Inc. has a twelve month low of $4.30 and a twelve month high of $18.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The company's 50-day simple moving average is $6.92 and its 200-day simple moving average is $8.09. The firm has a market cap of $458.83 million, a price-to-earnings ratio of -6.76 and a beta of 0.23.
Kezar Life Sciences (NASDAQ:KZR – Get Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. As a group, equities research analysts expect that Kezar Life Sciences, Inc. will post -1.03 earnings per share for the current year.Hedge Funds Weigh In On Kezar Life Sciences
Several hedge funds have recently made changes to their positions in KZR. Victory Capital Management Inc. lifted its holdings in shares of Kezar Life Sciences by 58.0% during the second quarter. Victory Capital Management Inc. now owns 2,770,098 shares of the company's stock valued at $22,909,000 after purchasing an additional 1,017,391 shares during the last quarter. Arizona State Retirement System purchased a new stake in Kezar Life Sciences during the second quarter valued at about $95,000. Trexquant Investment LP lifted its stake in Kezar Life Sciences by 173.8% during the second quarter. Trexquant Investment LP now owns 98,187 shares of the company's stock valued at $812,000 after buying an additional 62,326 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Kezar Life Sciences in the second quarter worth about $778,000. Finally, Virtus ETF Advisers LLC increased its position in shares of Kezar Life Sciences by 75.2% in the second quarter. Virtus ETF Advisers LLC now owns 21,970 shares of the company's stock worth $182,000 after acquiring an additional 9,427 shares in the last quarter. Institutional investors and hedge funds own 84.03% of the company's stock.
Wall Street Analyst Weigh In
Separately, Wells Fargo & Company cut their price target on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating on the stock in a report on Tuesday, January 3rd.
Kezar Life Sciences Company Profile
(Get Rating)
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
Featured Articles
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- 3 Hot Stocks The Analysts Are Buying
- Hertz Global Holding Could Be A Comfortable Ride In 2023
- Two Billionaires Are Rigging the Market. Here's How to Fight Back
- Should Investors Buy or Sell the Vaccinex Patent News?
- Take-Two Interactive Or Activision Blizzard: An Obvious Choice?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.